Dario Neri

Dario Neri's AcademicInfluence.com Rankings

Dario Neri

Chemistry

#2288

World Rank

#3178

Historical Rank

Organic Chemistry

#335

World Rank

#401

Historical Rank

chemistry Degrees

Dario Neri

Biology

#6510

World Rank

#9241

Historical Rank

Biochemistry

#838

World Rank

#945

Historical Rank

biology Degrees

Download Badge

Chemistry
Biology

Dario Neri's Degrees

Masters Chemistry University of Bologna
Bachelors Chemistry University of Bologna

Why Is Dario Neri Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dario Neri's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Interfering with pH regulation in tumours as a therapeutic strategy (2011) (1312)
Tumour vascular targeting (2005) (605)
Stereospecific nuclear magnetic resonance assignments of the methyl groups of valine and leucine in the DNA-binding domain of the 434 repressor by biosynthetically directed fractional 13C labeling. (1989) (568)
NMR determination of residual structure in a urea-denatured protein, the 434-repressor. (1992) (416)
Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin (2002) (337)
Design and Use of a Phage Display Library (1998) (313)
Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform (1997) (299)
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. (2003) (298)
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. (2002) (277)
Encoded self-assembling chemical libraries (2004) (254)
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature (2002) (249)
Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. (2001) (234)
Recent advances in osteosarcoma. (2014) (229)
Fibronectin as target for tumor therapy (2006) (229)
A high‐affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo‐vasculature in vivo (2008) (228)
A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. (2014) (225)
Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. (1999) (225)
DNA-Encoded Chemical Libraries: A Selection System Based on Endowing Organic Compounds with Amplifiable Information. (2018) (218)
A high-affinity human antibody that targets tumoral blood vessels. (1999) (206)
The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. (2007) (199)
Antibody-drug conjugates: basic concepts, examples and future perspectives. (2012) (194)
Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. (2003) (179)
DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries. (2014) (176)
Tumor-Targeting Properties of Novel Antibodies Specific to the Large Isoform of Tenascin-C (2006) (175)
Selective targeted delivery of TNFα to tumor blood vessels (2003) (172)
Design, construction, and characterization of a large synthetic human antibody phage display library (2005) (169)
A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation (2010) (167)
A portable albumin binder from a DNA-encoded chemical library. (2008) (165)
High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries (2008) (164)
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. (2010) (160)
Phage antibodies with pan‐species recognition of the oncofoetal angiogenesis marker fibronectin ED‐B domain (1996) (159)
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis (2009) (157)
In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. (2009) (153)
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. (2009) (153)
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. (2009) (149)
Immunocytokines: a novel class of potent armed antibodies. (2012) (148)
Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends (2011) (146)
Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation. (2015) (141)
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma (2011) (138)
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature (2005) (137)
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. (2002) (136)
Purification of biotinylated proteins on streptavidin resin: A protocol for quantitative elution (2004) (131)
Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment (1999) (130)
Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. (2002) (130)
High-affinity antigen binding by chelating recombinant antibodies (CRAbs). (1995) (129)
A traceless vascular-targeting antibody-drug conjugate for cancer therapy. (2012) (128)
Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries. (2013) (128)
Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents. (2015) (122)
Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study (2004) (121)
Selection of Carbonic Anhydrase IX Inhibitors from One Million DNA-Encoded Compounds. (2011) (121)
The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. (2007) (120)
Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. (1999) (118)
Molecular Imaging of Atherosclerotic Plaques Using a Human Antibody Against the Extra-Domain B of Fibronectin (2004) (115)
Flagellin Induces Myeloid-Derived Suppressor Cells: Implications for Pseudomonas aeruginosa Infection in Cystic Fibrosis Lung Disease (2013) (114)
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study (2015) (111)
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. (2014) (111)
Selective targeted delivery of TNFalpha to tumor blood vessels. (2003) (110)
Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy (2008) (109)
A strategy for the isolation of catalytic activities from repertoires of enzymes displayed on phage. (1999) (108)
Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. (2012) (106)
20 years of DNA-encoded chemical libraries. (2011) (106)
Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours (2009) (104)
Covalent linkage of the DNA repair template to the CRISPR-Cas9 nuclease enhances homology-directed repair (2018) (104)
Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. (2006) (104)
Engineered vascular‐targeting antibody‐interferon‐γ fusion protein for cancer therapy (2005) (103)
The use of phage display for the development of tumour targeting agents. (2000) (101)
Antibody-based targeting of the tumor vasculature. (2007) (99)
DNA‐encoded chemical libraries – achievements and remaining challenges (2018) (98)
Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin (2001) (97)
DNA-encoded chemical libraries: foundations and applications in lead discovery. (2016) (97)
Design and use of phage display libraries for the selection of antibodies and enzymes. (2000) (96)
Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia (2013) (96)
124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy (2009) (94)
Immunocytokines for cancer treatment: past, present and future. (2016) (93)
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. (2006) (93)
A Small-Molecule Inhibitor of Lin28. (2016) (92)
Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. (2012) (90)
Isolation of high-affinity trypsin inhibitors from a DNA-encoded chemical library. (2007) (90)
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. (2018) (90)
A Chemical Proteomics Approach for the Identification of Accessible Antigens Expressed in Human Kidney Cancer*S (2006) (90)
Biophysical methods for the determination of antibody-antigen affinities. (1996) (89)
Identification and relative quantification of membrane proteins by surface biotinylation and two‐dimensional peptide mapping (2005) (88)
Design and synthesis of a novel DNA-encoded chemical library using Diels-Alder cycloadditions. (2008) (87)
A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels (2011) (86)
Discovery of TNF inhibitors from a DNA-encoded chemical library based on diels-alder cycloaddition. (2009) (86)
Immunocytokines: a review of molecules in clinical development for cancer therapy (2013) (86)
Discovery of small-molecule interleukin-2 inhibitors from a DNA-encoded chemical library. (2012) (86)
The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. (2013) (85)
Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours (2013) (85)
New strategy for the extension of the serum half-life of antibody fragments. (2009) (84)
Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold (2018) (84)
The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel (2012) (83)
Non‐internalizing antibody–drug conjugates display potent anti‐cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix (2017) (83)
Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. (2009) (81)
Precise vicinal coupling constants3JHNα in proteins from nonlinear fits of J-modulated [15N,1H]-COSY experiments (1992) (81)
Optimized Reaction Conditions for Amide Bond Formation in DNA-Encoded Combinatorial Libraries. (2016) (80)
Isolated limb perfusion with the tumor‐targeting human monoclonal antibody–cytokine fusion protein L19‐TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma (2013) (79)
A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold. (2001) (79)
Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin (2006) (79)
The antibody‐based targeted delivery of interleukin‐4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer (2014) (79)
In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. (2010) (78)
Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects (2014) (78)
The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity (2013) (77)
A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Properties* (2007) (76)
An engineered antibody–interleukin‐12 fusion protein with enhanced tumor vascular targeting properties (2006) (74)
Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis (2007) (74)
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis (2008) (73)
DNA-encoded chemical libraries for the discovery of MMP-3 inhibitors. (2008) (72)
Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses (2014) (72)
Identification of structure-activity relationships from screening a structurally compact DNA-encoded chemical library. (2015) (72)
Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes (2002) (72)
Molecular targeting of angiogenesis. (2004) (72)
Automated screening for small organic ligands using DNA-encoded chemical libraries (2016) (71)
Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. (2011) (71)
Covalent DNA display as a novel tool for directed evolution of proteins in vitro. (2004) (70)
Support of1H NMR assignments in proteins by biosynthetically directed fractional13C-labeling (1992) (69)
Lack of specificity of endoglin expression for tumor blood vessels (2001) (69)
Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. (2006) (67)
Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format. (2012) (67)
The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. (2010) (66)
Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. (2011) (65)
Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis (2014) (65)
Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity (2019) (65)
In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. (2010) (64)
Identification of E-cadherin signature motifs functioning as cleavage sites for Helicobacter pylori HtrA (2016) (63)
Site-specific chemical modification of antibody fragments using traceless cleavable linkers (2013) (63)
Alanine substitutions in calmodulin-binding peptides result in unexpected affinity enhancement. (1996) (63)
Selection of single domain binding proteins by covalent DNA display. (2007) (63)
Determination of the nuclear magnetic resonance solution structure of the DNA-binding domain (residues 1 to 69) of the 434 repressor and comparison with the X-ray crystal structure. (1992) (62)
A heteronuclear three-dimensional NMR experiment for measurements of small heteronuclear coupling constants in biological macromolecules (1989) (62)
The use of biosensor technology for the engineering of antibodies and enzymes (1999) (61)
Tumor‐targeting properties of antibody–vascular endothelial growth factor fusion proteins (2002) (61)
Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study (2013) (61)
PHOTOACTIVE ANTIVIRAL AND CYTOTOXIC ACTIVITIES OF SYNTHETIC THIOPHENES AND THEIR ACETYLENIC DERIVATIVES (1989) (60)
Selective occlusion of tumor blood vessels by targeted delivery of an antibody‐photosensitizer conjugate (2006) (60)
Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma (2010) (60)
Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies (2012) (59)
New nuclear magnetic resonance experiment for measurements of the vicinal coupling constants 3JHN.alpha. in proteins (1990) (59)
In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature (2006) (59)
Expression of the Extra Domain B of Fibronectin, a Marker of Angiogenesis, in Head and Neck Tumors (2003) (58)
Antibody-based vascular tumor targeting. (2010) (58)
A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD+-Dependent Enzymes. (2019) (57)
High‐sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera (2016) (56)
A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice (2014) (56)
Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. (2009) (56)
Calmodulin as a Versatile Tag for Antibody Fragments (1995) (54)
Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. (2010) (54)
Ligand‐Based Vascular Targeting of Disease (2007) (54)
Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells. (2009) (54)
Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. (1999) (53)
Tumor targeting potential of the monoclonal antibody BC‐1 against oncofetal fibronectin in nude mice bearing human tumor implants (1997) (53)
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy. (2019) (53)
Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library. (2015) (53)
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. (2005) (53)
NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis. (1999) (52)
The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model. (2011) (52)
A non‐internalizing antibody‐drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo (2017) (52)
Complete 15N and 1H NMR assignments for the amino-terminal domain of the phage 434 repressor in the urea-unfolded form (1992) (51)
Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody–Drug Conjugates (2015) (51)
Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy (2014) (51)
Linker stability influences the anti‐tumor activity of acetazolamide‐drug conjugates for the therapy of renal cell carcinoma (2017) (50)
Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. (2016) (50)
Lead discovery by DNA-encoded chemical libraries. (2007) (50)
Sequence Determinants of a Microtubule Tip Localization Signal (MtLS)* (2012) (49)
Isolation of potent and specific trypsin inhibitors from a DNA-encoded chemical library. (2010) (49)
Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy. (2011) (48)
Immunocytokines are a promising immunotherapeutic approach against glioblastoma (2020) (48)
Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates. (2017) (48)
Site-specific and stoichiometric conjugation of cationic porphyrins to antiangiogenic monoclonal antibodies. (2010) (48)
Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients (2013) (48)
Emerging classes of armed antibody therapeutics against cancer (2014) (47)
Selection of streptavidin binders from a DNA-encoded chemical library. (2006) (47)
High-throughput sequencing for the identification of binding molecules from DNA-encoded chemical libraries. (2010) (47)
A comparison of different biotinylation reagents, tryptic digestion procedures, and mass spectrometric techniques for 2‐D peptide mapping of membrane proteins (2005) (47)
Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen. (2017) (46)
A Highly Functional Synthetic Phage Display Library Containing over 40 Billion Human Antibody Clones (2014) (46)
A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo (2016) (46)
Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD (2014) (46)
Isolation of a Small‐Molecule Inhibitor of the Antiapoptotic Protein Bcl‐xL from a DNA‐Encoded Chemical Library (2010) (45)
Phage-Derived Fully Human Monoclonal Antibody Fragments to Human Vascular Endothelial Growth Factor-C Block Its Interaction with VEGF Receptor-2 and 3 (2010) (45)
Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2 (2018) (45)
Different patterns of fibronectin and tenascin‐C splice variants expression in primary and metastatic melanoma lesions (2011) (45)
The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer (2015) (45)
On the magnitude of the chelate effect for the recognition of proteins by pharmacophores scaffolded by self-assembling oligonucleotides. (2006) (45)
Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. (2004) (44)
An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. (2002) (44)
Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [γ-32P]-ATP (1996) (44)
Modulation of gene expression by extracellular pH variations in human fibroblasts: A transcriptomic and proteomic study (2003) (44)
Studies of slow conformational equilibria in macromolecules by exchange of heteronuclear longitudinal 2-spin-order in a 2D difference correlation experiment (1991) (44)
Systematic evaluation and optimization of modification reactions of oligonucleotides with amines and carboxylic acids for the synthesis of DNA-encoded chemical libraries. (2014) (44)
Identification of the surface‐accessible, lineage‐specific vascular proteome by two‐dimensional peptide mapping (2008) (43)
Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes (2016) (43)
Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. (2000) (43)
DNA‐Encoded Chemical Libraries: A Tool for Drug Discovery and for Chemical Biology (2010) (43)
Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. (2001) (43)
Drug discovery with DNA-encoded chemical libraries. (2010) (42)
DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges. (2021) (42)
A proteomic approach for the identification of vascular markers of liver metastasis. (2010) (42)
Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 Gliomas and Correlation with 131I-SIP(L19), a Marker of Angiogenesis (2007) (42)
Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. (2019) (40)
High‐resolution analysis of the murine MHC class II immunopeptidome (2016) (40)
Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma (2016) (39)
A Specific and Covalent JNK-1 Ligand Selected from an Encoded Self-Assembling Chemical Library. (2017) (39)
A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia (2019) (39)
Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. (2004) (39)
Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. (2010) (38)
A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer (2011) (38)
Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (2014) (38)
Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy (2003) (38)
Support of 1H NMR assignments in proteins by biosynthetically directed fractional 13C-labeling. (1992) (37)
Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells (2019) (37)
Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse (2013) (37)
Antibody-Based targeting of angiogenesis. (2001) (36)
Molecular targeting of angiogenesis for imaging and therapy (2004) (36)
Preparation of phage antibodies to the ED-A domain of human fibronectin. (1998) (35)
A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo. (2007) (35)
Affinity-capture reagents for protein arrays. (2002) (35)
Human Antibody Against C Domain of Tenascin-C Visualizes Murine Atherosclerotic Plaques Ex Vivo (2007) (35)
Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies (2015) (34)
A DNA‐Encoded Library of Chemical Compounds Based on Common Scaffolding Structures Reveals the Impact of Ligand Geometry on Protein Recognition (2018) (34)
Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models (2007) (34)
Data‐Independent Acquisition of HLA Class I Peptidomes on the Q Exactive Mass Spectrometer Platform (2017) (34)
A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies (2010) (34)
Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site (2012) (33)
Advances in antibody engineering for rheumatic diseases (2019) (33)
Selection of catalytically active biotin ligase and trypsin mutants by phage display. (2001) (33)
Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment (2007) (33)
Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells (2020) (33)
Antibody-Based Delivery of IL2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice (2014) (33)
The Dose-Dependent Tumor Targeting of Antibody–IFNγ Fusion Proteins Reveals an Unexpected Receptor-Trapping Mechanism In Vivo (2014) (32)
Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method (2007) (32)
Tumor vascular targeting (2006) (31)
Noninternalizing targeted cytotoxics for cancer therapy. (2015) (31)
The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses (2017) (31)
A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination wiIh methotrexate. (2014) (31)
Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis. (2013) (31)
Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model. (2015) (31)
Screening of copper and palladium-mediated reactions compatible with DNA-encoded chemical libraries. (2019) (31)
Biological activities of terthiophenes and polyynes from the Asteraceae. (1993) (30)
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma (2014) (30)
Armed antibodies for cancer treatment: a promising tool in a changing era (2014) (29)
A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells. (2008) (29)
The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors (2020) (29)
Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis. (2006) (29)
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site (2016) (29)
Intralesional treatment of metastatic melanoma: a review of therapeutic options (2017) (29)
Dual-pharmacophore DNA-encoded chemical libraries. (2015) (28)
Potency-matched Dual Cytokine–Antibody Fusion Proteins for Cancer Therapy (2017) (28)
Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation. (2018) (28)
Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection (2010) (28)
Towards the design of an antibody that recognises a given protein epitope. (1999) (28)
Quantitative and Qualitative Analysis of Humoral Immunity Reveals Continued and Personalized Evolution in Chronic Viral Infection. (2020) (28)
A Chemically Defined Trifunctional Antibody–Cytokine–Drug Conjugate with Potent Antitumor Activity (2014) (28)
1H And 13C NMR chemical shifts of the diastereotopic methyl groups of valyl and leucyl residues in peptides and proteins (1990) (28)
An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications (2021) (27)
Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder (2006) (27)
Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma. (1997) (27)
Internalization via Antennapedia protein transduction domain of an scFv antibody toward c‐Myc protein (2008) (27)
Efforts toward the Total Synthesis of Tubulysins: New Hopes for a More Effective Targeted Drug Delivery to Tumors (2006) (27)
Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature (2013) (27)
Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19). (2006) (27)
Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3 (2010) (27)
Twenty‐five Years of DNA‐Encoded Chemical Libraries (2017) (27)
Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies. (2011) (27)
Hit‐Validation Methodologies for Ligands Isolated from DNA‐Encoded Chemical Libraries (2017) (27)
The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model (2015) (27)
Membranal and Blood‐Soluble HLA Class II Peptidome Analyses Using Data‐Dependent and Independent Acquisition (2018) (26)
Affinity Enhancement of Protein Ligands by Reversible Covalent Modification of Neighboring Lysine Residues. (2018) (26)
Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine (2018) (26)
1H,15N and13C NMR assignments of the 434 repressor fragments 1–63 and 44–63 unfolded in 7 M urea (1992) (26)
DeepQuanTR: MALDI‐MS‐based label‐free quantification of proteins in complex biological samples (2010) (26)
Quantitative Assessment of Affinity Selection Performance by Using DNA‐Encoded Chemical Libraries (2019) (26)
Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. (2010) (26)
Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies (2010) (26)
Ubiquitin Phosphorylation at Thr12 Modulates the DNA Damage Response. (2020) (26)
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients (2019) (25)
A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development. (2014) (25)
A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin (2011) (25)
The MHC Class II Immunopeptidome of Lymph Nodes in Health and in Chemically Induced Colitis (2017) (24)
Stereocontrolled synthesis of naturally occurring polyacetylenes characterized by (E)-1-en-3-yne, (E)-1-ene-3,5-diyne, (1E,5E)-1,5-dien-3-yne, and (1E,7E)-1,7-diene-3,5-diyne moieties (1988) (24)
Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation. (2014) (24)
Interrogating target-specificity by parallel screening of a DNA-encoded chemical library against closely related proteins. (2015) (23)
The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate (2012) (23)
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial (2020) (23)
Chemical proteomic and bioinformatic strategies for the identification and quantification of vascular antigens in cancer. (2010) (22)
Reformatting of scFv antibodies into the scFv-Fc format and their downstream purification. (2014) (22)
Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains (2018) (22)
ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions (2019) (22)
DNA-Compatible Diazo-Transfer Reaction in Aqueous Media Suitable for DNA-Encoded Chemical Library Synthesis. (2019) (22)
Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications. (2013) (22)
"Cap-and-Catch" Purification for Enhancing the Quality of Libraries of DNA Conjugates. (2015) (21)
Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient (2013) (21)
Targeted IL‐4 therapy synergizes with dexamethasone to induce a state of tolerance by promoting Treg cells and macrophages in mice with arthritis (2016) (20)
Recombinant antibodies for the depletion of abundant proteins from human serum (2006) (20)
Impact of a Central Scaffold on the Binding Affinity of Fragment Pairs Isolated from DNA‐Encoded Self‐Assembling Chemical Libraries (2017) (20)
Antibodies from phage display libraries as immunochemical reagents. (1998) (20)
Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications (2021) (19)
Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno peptidomes required for biomarker discovery (2017) (19)
B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? (2009) (19)
Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6. (2014) (19)
Expression of extra domain A containing fibronectin in chronic cardiac allograft rejection. (2011) (19)
Recombinant anti-human melanoma antibodies are versatile molecules. (1996) (19)
In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas (2018) (18)
The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity (2015) (18)
A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data. (2012) (18)
Two-dimensional mass spectrometric mapping. (2006) (18)
Improving Health by Investing in Medical Education (2005) (18)
Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis (2016) (17)
Staphylococcal Enterotoxins Dose-Dependently Modulate the Generation of Myeloid-Derived Suppressor Cells (2018) (17)
Critical evaluation of photocrosslinking parameters for the implementation of efficient DNA-encoded chemical library selections. (2020) (17)
A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors. (2019) (17)
A Single‐Stranded DNA‐Encoded Chemical Library Based on a Stereoisomeric Scaffold Enables Ligand Discovery by Modular Assembly of Building Blocks (2020) (17)
Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins* (2016) (17)
Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model (2018) (17)
Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily. (2014) (16)
Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin. (2013) (16)
Quantitative recovery of biotinylated proteins from streptavidin-based affinity chromatography resins. (2008) (16)
Expression of extradomain-B-containing fibronectin in subretinal choroidal neovascular membranes. (2003) (16)
De novo expression of fetal ED-A+ fibronectin and B+ tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection (2014) (16)
Ultraviolet-mediated antibiotic activity of synthetic thiophenes and their acetylenic derivatives (1989) (16)
Vascular tumor targeting. (2006) (16)
Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies. (2011) (16)
F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach (2018) (16)
A DNA-encoded chemical library based on peptide macrocycles. (2021) (16)
A fibrin-specific monoclonal antibody from a designed phage display library inhibits clot formation and localizes to tumors in vivo. (2014) (15)
Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA. (2010) (15)
Quantitative PCR is a Valuable Tool to Monitor the Performance of DNA‐Encoded Chemical Library Selections (2017) (15)
Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease (2015) (15)
Unexpected observation of concentration-dependent dissociation rates for antibody-antigen complexes and other macromolecular complexes in competition experiments. (2003) (14)
Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials. (2011) (14)
Calmodulin as an affinity purification tag. (2003) (14)
Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma. (2015) (14)
Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA (2021) (14)
Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity. (2018) (14)
A Microdosing Study with 99mTc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients (2020) (14)
Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis (2011) (14)
Evaluation of antibody–chemokine fusion proteins for tumor-targeting applications (2014) (14)
Targeted delivery of interleukin-10 to chronic cardiac allograft rejection using a human antibody specific to the extra domain A of fibronectin. (2015) (14)
Combinations of the immunocytokine F16-IL2 with doxorubicin or with paclitaxel investigated in phase Ib studies in patients with advanced solid tumors. (2010) (14)
A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer (2014) (14)
Induction of Myeloid-Derived Suppressor Cells in Cryopyrin-Associated Periodic Syndromes (2016) (13)
Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery (2012) (13)
Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments. (2017) (13)
Engineering recombinant antibodies for immunotherapy (1995) (13)
Multipurpose high sensitivity luminescence analyzer (LUANA): use in gel electrophoresis. (1996) (13)
Design and construction of a naïve mouse antibody phage display library. (2010) (13)
A novel reactive ester derivative of biotin with reduced membrane permeability for in vivo biotinylation experiments (2010) (13)
Chronic cardiac allograft rejection: critical role of ED‐A+ fibronectin and implications for targeted therapy strategies (2012) (13)
Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. (2015) (12)
Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure. (2013) (12)
Methods for the identification of vascular markers in health and disease: from the bench to the clinic. (2010) (12)
An engineered 4-1BBL fusion protein with “activity on demand” (2020) (12)
Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression (2016) (12)
Antibody-Mediated Delivery of VEGFC Ameliorates Experimental Chronic Colitis. (2019) (11)
B domain containing Tenascin-C: a new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder? (2011) (11)
Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis (2018) (11)
Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice (2019) (11)
Detection of Soluble ED-A+ Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling (2016) (11)
A new simplified method for preparation of a synthetic phage antibody with practically acceptable detection sensitivity on immunoblots. (2001) (10)
Efficient one-step direct labelling of recombinant antibodies with technetium-99m (1995) (10)
A NEW SYNTHETIC ROUTE TO 2,2':5',2 -TERTHIOPHENE-5-DERIVATIVES TO CONJUGATE WITH PROTEINS AND MONOCLONAL ANTIBODIES (1996) (10)
Antibody-based targeting of angiogenesis. (2001) (10)
From target discovery to clinical trials with armed antibody products. (2014) (10)
Precise vicinal coupling constants 3JHN alpha in proteins from nonlinear fits of J-modulated [15N,1H]-COSY experiments. (1992) (9)
Activation of T cells via tumor antigen specific chimeric receptors: The role of the intracellular signaling domain (2003) (9)
Improved protein sequence coverage by on resin deglycosylation and cysteine modification for biomarker discovery (2009) (9)
Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin. (2019) (9)
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy (2021) (9)
Recombinant antibodies for the selective targeting of tumor neovasculature. (2002) (9)
A dose finding pharmacokinetic study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors (2007) (9)
F8-SIP mediated targeted photodynamic therapy leads to microvascular dysfunction and reduced glioma growth (2016) (9)
A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies (2018) (9)
A phase I study of weekly oxaliplatin (OXA), 5-fluorouracil (5-FU) continuous infusion and preoperative radiotherapy in locally advanced rectal cancer (2001) (9)
Affinity selections of DNA-encoded chemical libraries on carbonic anhydrase IX-expressing tumor cells reveal a dependence on ligand valence. (2021) (9)
An antibody-based enzymatic therapy for cancer treatment: The selective localization of D-amino acid oxidase to EDA fibronectin. (2021) (9)
Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia. (2019) (8)
Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells. (2021) (8)
Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids (2015) (8)
Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads. (2018) (8)
Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma1 (2017) (8)
The accessible cerebral vascular proteome in a mouse model of cerebral β-amyloidosis. (2011) (8)
Comparative evaluation of DNA-encoded chemical selections performed using DNA in single-stranded or double-stranded format. (2020) (8)
Two general methods for the isolation of enzyme activities by colony filter screening. (2002) (8)
Targeted siRNA nanocarrier: a platform technology for cancer treatment (2022) (8)
A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo (2020) (8)
A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake (2022) (8)
A universal reporter cell line for bioactivity evaluation of engineered cytokine products (2019) (7)
A small-molecule inhibitor of Lin 28 (2016) (7)
On-DNA hit validation methodologies for ligands identified from DNA-encoded chemical libraries. (2020) (7)
Selective Fragments for the CREBBP Bromodomain Identified from an Encoded Self‐assembly Chemical Library (2020) (7)
Human T cells modulate myeloid-derived suppressor cells through a TNF-α-mediated mechanism. (2018) (7)
Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response of tissue‐resident memory T cells against the AH1 rejection antigen (2019) (7)
Proteomics application exercise of the Swiss Proteomics Society: Report of the SPS'02 session (2003) (7)
Large screening of DNA-compatible reaction conditions for Suzuki and Sonogashira cross-coupling reactions and for reverse amide bond formation. (2021) (7)
Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation. (2019) (6)
Targeted ED-B fibronectin SPECT in vivo imaging in experimental atherosclerosis. (2015) (6)
The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors (2020) (6)
A technetium 99 m-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo (2016) (6)
Monoclonal antibodies to murine thrombospondin-1 and thrombospondin-2 reveal differential expression patterns in cancer and low antigen expression in normal tissues. (2014) (6)
A monoclonal antibody prevents aggregation of the NBD1 domain of the cystic fibrosis transmembrane conductance regulator. (2007) (6)
An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia (2018) (6)
FRI0194 A phase IB clinical trial with dekavil (F8-IL10), an anti-inflammatory immunocytokine for the treatment of rheumatoid arthritis, used in combination with methotrexate (2013) (5)
Impact of ligand size and conjugation chemistry on the performance of universal chimeric antigen receptor T-cells for tumor killing. (2020) (5)
SAT0232 A Phase IB Clinical Trial in Rheumatoid Arthritis of Dekavil (F8-IL10), A Novel Anti-Inflammatory Immunocytokine (2014) (5)
Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naïve stage IV melanoma patients. (2010) (5)
Immunoscintigraphic Detection of the EDB Domain of Fibronectin , a Marker of Angiogenesis , in Patients with Cancer 1 (2003) (5)
Ligand‐based Targeting of Disease: From Antibodies to Small Organic (Synthetic) Ligands (2008) (5)
A Novel Antibody–IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis (2021) (5)
Therapeutic Evaluation of Antibody-Based Targeted Delivery of Interleukin 9 in Experimental Pulmonary Hypertension (2021) (5)
Immunotherapy with Immunocytokines and PD-1 Blockade Enhances the Anticancer Activity of Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX (2020) (5)
An Antibody-Tumor Necrosis Factor Fusion Protein that Synergizes with Oxaliplatin for Treatment of Colorectal Cancer (2019) (5)
Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma (2008) (5)
Covalent linkage of the DNA repair template to the CRISPR/Cas9 complex enhances homology-directed repair (2017) (5)
A Monoclonal Antibody to Human DLK1 Reveals Differential Expression in Cancer and Absence in Healthy Tissues (2015) (5)
Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade (2019) (5)
A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas (2019) (5)
P104 Radioimmunotherapy of Head and Neck Cancer Xenografts Using 131I-L19-SIP for Selective Targeting of Tumor Vasculature (2006) (4)
Sortase-Mediated Site-Specific Modification of Interleukin-2 for the Generation of a Tumor-Targeting Acetazolamide–Cytokine Conjugate (2020) (4)
Affinity Enhancement of Protein Ligands by Reversible Covalent Modification of Neighboring Lysine Residues (2018) (4)
Specific Inhibitor of Placental Alkaline Phosphatase Isolated from a DNA-Encoded Chemical Library Targets Tumor of the Female Reproductive Tract. (2021) (4)
Reflections on DNA-encoded chemical libraries. (2020) (4)
Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12. (2016) (4)
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas. (2021) (4)
Complexation with a cognate antibody fragment facilitates affinity measurements of fluorescein-linked small molecule ligands. (2020) (4)
Cancer therapy in mice using a pure population of CD8+ T cell specific to the AH1 tumor rejection antigen (2021) (4)
A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions. (2014) (4)
A novel fully-human potency-matched dual cytokine-antibody fusion protein targets carbonic anhydrase IX in renal cell carcinomas (2019) (4)
Limited efficacy of intratumoral IL-2 applied to large melanoma metastases (2014) (4)
Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses. (2014) (4)
SAT0196 Dekavil (F8-IL10), A Novel Therapeutic Approach for Rheumatoid Arthritis: Ongoing Phase IB Clinical Trial Results (2015) (4)
Antibody-Drug Conjugates: Targeting the Tumor Microenvironment (2018) (4)
The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune check-point inhibitors (2019) (3)
Phase I study with antifibronectin I-131 L19-SIP: First dosimetric and therapeutic results (2007) (3)
Automated and enhanced extraction of a small molecule-drug conjugate using an enzyme-inhibitor interaction based SPME tool followed by direct analysis by ESI-MS (2019) (3)
Antibody-based delivery of interleukin-9 to neovascular structures: Therapeutic evaluation in cancer and arthritis (2020) (3)
Advances in Brief Inhibition of Tumor Angiogenesis by a Single-chain Antibody Directed against Vascular Endothelial Growth Factor 1 (2000) (3)
Selection and characterization of human antibody fragments specific for psoriasin - a cancer associated protein. (2012) (3)
Arginase 1+ IL‐10+ polymorphonuclear myeloid‐derived suppressor cells are elevated in patients with active pemphigus and correlate with an increased Th2/Th1 response (2021) (3)
Highly fluorescent protein labeling using dendritic peptide derivatives. (2000) (3)
Discovery and investigation of lead compounds as binders to the Extra‐Domain B of the angiogenesis marker, fibronectin (2003) (3)
Anti-human CD117 CAR T-cells efficiently eliminate hematopoietic stem and CD117-positive AML cells (2018) (3)
An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease (2021) (3)
A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis (2019) (3)
Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo (2020) (3)
A1 AND D DOMAIN OF TENASCIN C – NEW PROGNOSTIC MARKER IN BLADDER CANCER (2008) (3)
Targeted delivery of tissue factor to tumor neovasculature for cancer therapy. (2001) (3)
Mass Spectrometry-Based Method for the Determination of the Biodistribution of Tumor-Targeting Small Molecule-Metal Conjugates. (2022) (2)
Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice. (2019) (2)
Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics (2022) (2)
Targeting the Vascular Endothelium – Novel Approaches (2003) (2)
Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody (2022) (2)
Identification and Validation of New Interleukin-2 Ligands Using DNA-Encoded Libraries. (2021) (2)
Immunocytokines for Cancer Therapy (2014) (2)
The immunological basis of tumor therapy by targeted delivery of TNFa to tumor vessels (2006) (2)
Acoustic Echo Cancellation on the Adaptive Multi-Rate Speech Codec Parameters (2008) (2)
Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade (2022) (2)
NMR Structure of the Angiogenesis Marker Oncofoetal Fibronectin ED-B Domain (1999) (2)
A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse (2021) (2)
Radioimmunotherapy (RIT) with 131l-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial. (2010) (2)
Preliminary evaluation of radioimmunotherapy with Tenarad, a I-131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin lymphoma. (2011) (2)
Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression (2020) (2)
Half‐Life Extension by Binding to Albumin through Small Molecules (2012) (2)
Correction to "A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD+-Dependent Enzymes". (2021) (2)
SAT0108 Dekavil (F8-Il10): A Novel Anti-Inflammatory Immunocytokine for the Treatment of Rheumathoid Arthritis (2013) (2)
Author response: Covalent linkage of the DNA repair template to the CRISPR-Cas9 nuclease enhances homology-directed repair (2018) (2)
Results of a phase I/II dose-finding and efficacy study of the tumor-targeting 131I-L19SIP human recombinant mini-antibody in patients (pts) with cancer (2010) (2)
Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21 (2022) (2)
Phase I study of F16IL2 antibody–cytokine fusion with very low‐dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation (2021) (2)
What Is a Biosimilar (2015) (2)
A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake (2022) (2)
Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients. (2016) (2)
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse (2022) (2)
Antibody-Based Targeting of Tumor Vasculature and Stroma (2011) (2)
Recombinant proteins L and LG (2007) (2)
Affinity Measurements by Band Shift and Competition ELISA (2001) (2)
Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice (2019) (1)
A dose confirmation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine in patients with metastatic melanoma. (2011) (1)
In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma (2018) (1)
OC-0051: Radiotherapy causes long-lasting antitumor immunological memory when combined with immunotherapy (2018) (1)
Targeting Interleukin-2 to the Neovasculature Potentiates Rituximab‘s Activity Against Mantle Cell Lymphoma in Mice (2012) (1)
rituximab in combination with the immunocytokine L 19-IL 2 Complete eradication of human B-cell lymphoma xenografts using (2009) (1)
Encoding chemistry. (2009) (1)
Use of Human Recombinant Antibodies to the Marker of Angiogenesis Ed-B in Cancer Therapy (2001) (1)
The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer. (2020) (1)
“Dekavil” cytokine fusion protein automated iodine-124 radiolabelling for PET imaging: production, QC & biodistribution studies in mice (2015) (1)
Voice Activity Detection Based on the Adaptive Multi-Rate Speech Codec Parameters (2008) (1)
Antibody reproducibility challenges: the solution lies in the sequence (2016) (1)
Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors (2020) (1)
Cancer esearch or and Stem Cell Biology ivo Imaging of Inflammation-and Tumor-Induced Lymph e Lymphangiogenesis by Immuno – Positron R ission Tomography (2010) (1)
Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells (2021) (1)
285MO The combination of lomustine and antibody-based targeted TNF (L19TNF) as a promising treatment for recurrent glioblastoma (2022) (1)
Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy (2022) (1)
Complete 15 N and 1 H NMR assignments for the amino-terminal domain of the phage 434 repressor in the urea-unfolded form ( sequence-specific NMR assignments / protein denaturation / protein folding / isotope-labeled proteins ) (1)
A Bispecific Antibody Targeting CD117 and CD3 Enables T Cell Mediated Killing of CD117-Expressing Healthy and Malignant Hematopoietic Cells (2021) (1)
Selective tumor targeting enabled by picomolar fibroblast activation protein inhibitors isolated from a DNA-encoded affinity maturation library (2022) (1)
Discovery, affinity maturation and multimerization of small molecule ligands against human tyrosinase and tyrosinase-related protein 1 (2020) (1)
The Discovery and Characterisation of Tumour Endothelial Markers (2010) (1)
Universal encoding of next generation DNA-encoded chemical libraries (2022) (1)
OC-0157 Radiation and immunotherapy to fight cancer: a 'pushing the gas and releasing the brakes' approach. (2019) (1)
AB0364 A Novel Approach for Rheumatoid Arthritis: Results of The Ongoing Clinical Trials with The Fully Human Immunocytokine Dekavil (F8-IL10) (2016) (1)
Inference of molecular structure for characterization and improvement of clinical grade immunocytokines. (2021) (1)
Modular assembly and encoding strategies for dual-display DNA-encoded chemical libraries (2021) (1)
Supplementary Material for: Induction of Myeloid-Derived Suppressor Cells in Cryopyrin-Associated Periodic Syndromes (2016) (1)
1095TiP Daromun, a dermato-oncology drug in development for stage III and IV melanoma and non-melanoma skin cancers: A clinical overview (2021) (1)
Small Targeted Cytotoxics: Current State and Promises from DNA-Encoded Chemical Libraries (2013) (1)
Selections for enzymatic catalysts (2005) (1)
Design and characterisation of a novel interleukin-15 receptor alpha fusion protein and analysis of interleukin-15 complexation (2019) (1)
Sortase-mediated site-specific modification of interleukin-2 for the generation of a tumor targeting acetazolamide-cytokine conjugate (2020) (1)
Imaging T Cells In Vivo (2015) (1)
Therapeutic approaches to hepatocellular carcinoma (2008) (1)
Antibody‐Based Vascular Targeting: Proteomic Techniques for the Identification and Quantification of Membrane Proteins on Endothelial Cells (2004) (1)
Editorial overview: Next generation therapeutics: Creating and exploiting the chemistry of large numbers. (2015) (0)
A New Synthetic Route to 2,2′:5′,2′′‐Terthiophene‐5‐derivatives to Conjugate with Proteins and Monoclonal Antibodies. (1997) (0)
Targeting tumour vasculature in human colorectal xenografts using against the extra-domain B of fibronectin (2005) (0)
Abstract 758: Head-to-head comparison of ADC and SMDC products, alone and in combination with antibody-IL2 fusion proteins (2018) (0)
Gutbrodt Activity Against Acute Myeloid Leukemia Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent (2013) (0)
Targeting the Endothelium in Cancer : Basic Mechanisms and Novel Drug Development (2003) (0)
L19 diabody fragment from immunocytokine L19-IL2 (2021) (0)
ヒトカゼインキナーゼII及び[γ‐32P]ATPを用いたりん酸化による組換体断片の放射活性標識化 (1996) (0)
De novo expression of fetal ED-A+ fibronectin and B+ tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection (2014) (0)
The structure of antigens vol. 2 (1994) (0)
Engineering murine GITRL for antibody-mediated delivery to tumor-associated blood vessels (2020) (0)
Preliminary evaluation of radioimmunotherapy with an 131I labelled small immunoprotein targeted against the extra domain B of fibronectin in combination with whole brain radiation therapy in patients with multiple brain metastases from solid tumors. (2011) (0)
Combination of a fusion protein of an antibody directed against the EDB fibronectin-IL-2, and a molecule binding to B cells, progenitors of B lymphocytes and / or their cancerous counterpart (2008) (0)
Anticorps contre la tenascine-C (2005) (0)
The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate (2011) (0)
P76 Clinical experiences with therapeutic derivatives of the anti-ED-B fibronectin immunoprotein L19 (2007) (0)
20 Years of DNA‐Encoded Chemical Libraries (2012) (0)
Abstract SY28-04: Targeting the tumor extracellular matrix with armed antibodies (2012) (0)
Abstract 2436: The Human Antibody against the C Domain of Tenascin-C images Murine Atherosclerotic Plaques ex vivo (2006) (0)
Engineering recombinant antibodies for medical applications (2000) (0)
PHASE I/II STUDY OF THE TUMOUR-TARGETING HUMAN L19- IL2 MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (2008) (0)
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia (2022) (0)
Special Lecture: Development compounds with different modes of action for the treatment of pancreatic and hepatocellular carcinomas: ZK 304709 and L19-IL-2 (2006) (0)
239 Paclitaxel enhances therapeutic efficacy of F8-antibody mediated delivery of interleukin-2 to xenografted melanoma cancer (2010) (0)
Abstract SY35-04: Arming tumor-targeting antibodies with cytokine payloads: Emerging clinical results (2015) (0)
NMR STRUCTURE OF THE FIBRONECTIN ED-B DOMAIN, NMR, 20 STRUCTURES (1998) (0)
1045-189 Plaque targeting in atherosclerotic mice using a small immunoprotein against an angiogenesis-associated fibronectin isoform (2004) (0)
Cover Feature: A DNA-Encoded Library of Chemical Compounds Based on Common Scaffolding Structures Reveals the Impact of Ligand Geometry on Protein Recognition (ChemMedChem 13/2018) (2018) (0)
OC-0249: Radiotherapy and L19-IL2 are able to synergize: long-lasting antitumor effects (2014) (0)
Selection of high-affinity human monoclonal antibodies specific to the constant domain of versican as tools for tumor targeting (2008) (0)
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial (2020) (0)
IMMU-07. TUMOR STROMA–TARGETING ANTIBODY-CYTOKINE CONJUGATES TO CONVERT THE IMMUNOLOGICALLY COLD GLIOMA MICROENVIRONMENT INTO A HOT ONE (2020) (0)
Large Molecule Therapeutics Antibody-Based Delivery of IL 2 and Cytotoxics Eradicates Tumors in Immunocompetent Mice (2014) (0)
Abstract 5553: A novel immunocytokine for the treatment of cancer (2018) (0)
A novel reactive ester derivative of biotin with reduced membrane permeability for in vivo biotinylation experiments (2011) (0)
Drug Targeting Mini-Symposium of the Division for Medicinal Chemistry (DMC) of the Swiss Chemical Society (SCS), at the Department of Chemistry, University of Basel, May 29, 2008 (2008) (0)
The ED-A fibrinogen antigen is associated with neovasculature tumor metastases (2008) (0)
SYST-03. A PHASE I/II STUDY TO EVALUATE SAFETY AND PRELIMINARY ACTIVITY OF THE TUMOR-TARGETING ANTIBODY-CYTOKINE FUSION PROTEIN L19TNF IN PATIENTS WITH GLIOBLASTOMA AT FIRST RELAPSE (2021) (0)
to tumor blood vessels α Selective targeted delivery of TNF (2013) (0)
Traitement du cancer (2009) (0)
Targeted Interleukin‐9 delivery in pulmonary hypertension: Comparison of immunocytokine formats and effector cell study (2022) (0)
936 Targeted activation of lymphatic vessels in inflamed skin potently inhibits skin inflammation (2018) (0)
15. Dual-Pharmacophore DNA-Encoded Chemical Libraries (2014) (0)
High expression of tenascin-C extra domains, markers of angiogenesis, in human lung cancer. (2006) (0)
61: Immunosensitization through radiotherapy: the example of immunocytokines (2014) (0)
Abstract B55: Phase I/II study of the tumor‐targeting human L19TNF‐monoclonal antibody‐cytokine fusion protein in patients with advanced solid tumors (2009) (0)
Identification of accessible proteins expressed in human breast cancer (2006) (0)
378TiP A phase I/II/IIb study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma (2021) (0)
Large Molecule Therapeutics A Chemically De fi ned Trifunctional Antibody – Cytokine – Drug Conjugate with Potent Antitumor Activity (2014) (0)
Targeting tumour vasculature in human colorectal xenografts using an antibody against the extra-domain B of fibronectin. BACR/BMS Tumour vasculature: New targets and Therapies (2006) (0)
Translational imaging of the Fibroblast Activation Protein (FAP) using the new ligand Ga-68-OncoFAP-DOTAGA (2022) (0)
Abstract 2768: Potentiating the action of antibody-dependent cell-mediated cytotoxicity with immunocytokines (2018) (0)
DDRE-21. LOMUSTINE AND TARGETED-CYTOKINE THERAPY: A BENEFICIAL LIAISON FOR RECURRENT GLIOBLASTOMA (2021) (0)
DNA‐Encoded Chemical Libraries: A Tool for Drug Discovery and for Drug Discovery and for Chemical Biology (2010) (0)
Evaluating prediction strategies for identification of immunogenic mutation-derived neo-epitopes in melanoma (2016) (0)
CORRIGENDUM: In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature (2005) (0)
P2-042: High expression of Tenascin-C extra domains, markers of angiogenesis, in human lung cancer (2007) (0)
Il2 and tnf mutant immunoconjugates (2017) (0)
48 Targeting melanoma using a single-chain - IL-2 fusion protein (1997) (0)
Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response against the AH1 tumor rejection antigen (2019) (0)
BST-2 as a target for antibody-based therapy In vivo biotinylation of the vasculature in B-cell lymphoma identifies (2013) (0)
Special edition on DNA-Encoded chemical libraries. (2020) (0)
Abstract 589: Targeting of metastatic osteosarcoma with F8-TNF-alpha in an orthotopic mouse model (2016) (0)
A mass spectrometry-based method for the determination of in vivo biodistribution of tumor targeting small molecule-metal conjugates (2022) (0)
Based on Maytansinoids Drug Conjugates − Curative Properties of Noninternalizing Antibody (2014) (0)
Selection of a PD‐1 blocking antibody from a novel fully human phage display library (2022) (0)
Coded, self-assembling-chemical libraries (esachel) (2002) (0)
Promotion of Lymphangiogenesis by Targeted Delivery of VEGF-C Improves Diabetic Wound Healing (2023) (0)
Low molecular weight drug conjugates for binding to carbonic anhydrase ix (2015) (0)
OC-0234: Radiotherapy and L19-IL2: perfect match for an abscopal effect with long-lasting memory (2016) (0)
Antibodies against the ED-B domain of fibronectin, conjugates containing them and their use for the diagnosis and treatment of tumors and diseases associated with angiogenesis (1999) (0)
Antibodies against the ED-B domain of fibronectin, antibodies containing such conjugates, and their use for diagnosis and therapy of angiogenesis-associated diseases and tumors (1999) (0)
Antigen ED-A of fibrinogen is associated with lymphomas (2008) (0)
Abstract 2785: Potency-matched dual cytokine antibody fusion proteins in combination with PD-L1 blockade (2018) (0)
Targeted photolysis of melanoma cells by Alfa-Terthienyl derivative labeled antimelanoma monoclonal antibody (1996) (0)
Next generation therapeutics. (2009) (0)
Conjugués anticorps-médicament (2014) (0)
1554TiP A randomized phase II study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced or metastatic soft tissue sarcoma (2021) (0)
Evaluating prediction strategies for identification of T cell responsive mutation-derived neoepitopes in cancer (2016) (0)
Phase I study of anti fibronectin 131I-L19-small immunoprotein (SIP): Preliminary dosimetric, pharmacokinetics (PK) and therapeutic results (2007) (0)
Histochemical analysis of arthritc paw sections (2011) (0)
Targeting the extradomain A of fibronectin allows identification of vascular resistance to antiangiogenic therapy in experimental glioma (2018) (0)
FROM INTACT ANTIBODIES TO ARMED ANTIBODIES (2014) (0)
The immunocytokine L19-TNF eradicates Sarcomas in combination with Chemotherapy or with immune check-point inhibitors (2019) (0)
Extra cellular matrix remodelling in chronic cardiac allograft rejection (2011) (0)
A Phage Display-Generated Fully Human Anti-IL-7Rα Antibody Shows Anti-Tumor Activity Against T-Cell Acute Lymphoblastic Leukemia (2018) (0)
Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery (2011) (0)
Regio- and stereoselective synthesis of (2E,6E,8E)-N-(2-methylpropyl)-2,6,8-hexadecatriene-10-ynamide, a naturally-occurring acetylenic substance (1987) (0)
delivery to the tumor blood vessel extracellular matrix Enhancement of the antitumor properties of interleukin-2 by its targeted (2013) (0)
Immunoliposomes for the simultaneous targeted inhibition of angiogenesis and tumor growth (1999) (0)
This information is current as Induced Colitis Lymph Nodes in Health and in Chemically The MHC Class II Immunopeptidome of Bootz and (2016) (0)
Cardiac accumulation of a human recombinant antibody recognizing ED-A+ fibronectin after heterotopic rat heart transplantation in vivo: A new strategy to detect and treat chronic cardiac allograft rejection? (2013) (0)
Radiotherapy and the immunocytokine L19-IL2: a perfect match for an abscopal effect with long-lasting memory (2016) (0)
Calmodulin-tagged phage and two-filter sandwich assays for the identification of enzymatic activities. (2003) (0)
Targeting the tumour vasculature: therapeutic efficacy of a 131I-labeled antibody against the ED-B domain of fibronectin. (2006) (0)
Back Cover: Quantitative PCR is a Valuable Tool to Monitor the Performance of DNA‐Encoded Chemical Library Selections (ChemBioChem 9/2017) (2017) (0)
1553TiP A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma (2021) (0)
Analysis of ED-A+ fibronectin expression after heterotopic rat heart transplantation: association to cardiac allograft rejection and implications for targeted post-transplant therapy (2010) (0)
640 Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent anti-tumor immunity against treatment-refractory glioblastoma (2022) (0)
A universal reporter cell line for bioactivity evaluation of engineered cytokine products (2020) (0)
Large scale comparative proteomic study of accessible vascular proteins in mouse liver metastases and normal liver (2008) (0)
Targeting glioblastoma with novel immunocytokines. (2020) (0)
PO-428 Radiotherapy, immunocytokines and immune checkpoint inhibitors: finding the optimal combination (2018) (0)
OC-0055: Immunocytokine, immune checkpoint inhibitor and radiotherapy: finding the right combination (2018) (0)
Publisher Correction: Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications (2021) (0)
Fibroblast Activation Protein triggers release of drug payload from non-internalizing small molecule-drug conjugates in solid tumors. (2022) (0)
Photodynamic Therapy of Rabbit Corneal Neoascularization with Photosensitizer Conjugated to Antibody against the Extradomain–B of Fibronectin (2004) (0)
Efficient utilization of available sequence space : generation of hAbs for medicine through consensus human Ab library and trinucleotide-based mutagenesis method (2012) (0)
Antibody-Inspired Affinity Measurements of Fluorescein-Linked Small Molecule Ligands (2020) (0)
466 Antibody therapies targeting the stromal compartment (2004) (0)
In vivo targeting of tumour neo-vasculature with high-affinity recombinant antibodies (1997) (0)
new antigen associated with tumor neovasculature metastases (2008) (0)
Efficient Human Acute Myeloid Leukemia Targeting By Universal Chimeric Antigen Receptor T-Cells Via Combinatorial Use of Linkers (2021) (0)
OP0108 The Antibody-Based Delivery of IL4 to the Neo-Vasculature Cures Mice with Arthritis (2014) (0)
14 INVITED Vascular targeting (2006) (0)
Advanced T-Cell Engineering for Cancer Therapy (ATECT). (2015) (0)
Domain antibodies eb-d fibronectin conjugates containing them and use of them for the diagnosis and therapy of tumors and diseases associated with angiogenesis. (1999) (0)
Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study (vol. 4, Issue 6, pp. 1737‐1760) (2004) (0)
Abstract 3386:In vivoimaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography (2010) (0)
Abstract 3811: Targeted Interleukin 2 and synergy with immune check-point inhibitors (2018) (0)
Vascular targeting antibodies: from the bench to the clinic (2008) (0)
Identification and characterization of new blood-accessible colorectal cancer biomarkers (2008) (0)
1074 A novel fully human CD28 antibody that cross-reacts with CTLA-4 and mouse CD28 for potential applications in cancer immunotherapy (2022) (0)
Abstract LB522: Fibroblast activation protein triggers the release of drug payload from non-internalizing small molecule-drug conjugates in solid tumors (2022) (0)
Abstract LB527: A novel dimeric small molecule-radio conjugate targeting fibroblast activation protein with high and prolonged tumor uptake (2022) (0)
Abstract 5744: Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation (2023) (0)
Addition of a tumor-targeting antibody-interleukin-2 fusion enhances the anti-cancer efficacy of FAP-directed radioligand therapy in mice (2023) (0)
900 Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation (2022) (0)
An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties (2023) (0)
Abstract 1877: Tripokin: potential best-in-class for tumor targeted interleukin-2 (IL2) potentiated by tumor necrosis factor (TNF) (2023) (0)
Abstract 1988: FAP-targeted non-internalising drug conjugates: A comparative evaluation between small molecules, antibodies and peptides (2023) (0)
Isolation of a Natural Killer Group 2D Small‐Molecule Ligand from DNA‐Encoded Chemical Libraries (2022) (0)
Abstract 2838: Tumor-targeted interleukin-2 enhances the anti-cancer activity of multivalent OncoFAP radioligand therapeutics (2023) (0)
1093 A novel IL12-based immunocytokine targeting fibroblast activation protein (FAP) for the treatment of cancer (2022) (0)
Abstract LB535: A novel IL12-based immunocytokine targeting fibroblast activation protein (FAP) for the treatment of cancer (2022) (0)
Abstract 1987: Delivery of potent cytotoxic camptothecin derivatives to tumors by OncoFAP-based small molecule-drug conjugates (2023) (0)
CTIM-22. THE COMBINATION OF LOMUSTINE AND THE IMMUNOCYTOKINE L19TNF IS A PROMISING TREATMENT FOR RECURRENT GLIOBLASTOMA (2022) (0)
Abstract 1989: DNA-encoded affinity maturation libraries enable the discovery of low picomolar fibroblast activation protein inhibitors suitable for radioligand therapy of solid tumors (2023) (0)
An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions (2023) (0)
A deep learning approach for the discovery of tumor-targeting small organic ligands from DNA-Encoded Chemical Libraries (2023) (0)
Antibody-Mediated Delivery of VEGF-C Promotes Long-Lasting Lymphatic Expansion That Reduces Recurrent Inflammation (2022) (0)
[Diffusion of smoking among high school students at U.S.L. No. 18 of the Tuscan region]. (1989) (0)
OC-0084: Combining RT with L19-IL2 and aPDL1: from preclinical results towards a phase II trial (ImmunoSABR). (2020) (0)
Moderated poster sessionMP-12: Bladder cancer - basic researchMP-12.02: Prognostic value of the differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder (2006) (0)
Dosimetry of 131I-L19SIP in Patients with Solid Tumors and Hematologic Malignancies: Final Results of First-in-human Trial (2010) (0)
OS08.7.A Lomustine and the immunocytokine L19TNF are a promising treatment combination for recurrent glioblastoma (2022) (0)
PReS-FINAL-2336: Induction of MDSCS in Muckle-Wells syndrome (2013) (0)
Fibrosis Lung Disease Infection in Cystic Pseudomonas aeruginosa Suppressor Cells: Implications for Flagellin Induces Myeloid-Derived (2013) (0)
1516 Genetic mouse models and a new pro-lymphangiogenic treatment approach reveal beneficial effects of lymphatic vessel activation in cutaneous wound healing (2023) (0)
PW02-042 - Induction of MDSC in Muckle-Wells syndrome (2013) (0)
WS5.6 Regulatory T cells in cystic fibrosis patients infected with Pseudomonas aeruginosa (2013) (0)
Acute lymphoblastic leukemia A fully human anti-IL-7 R α antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia (2019) (0)
Cover Feature: Affinity Selections of DNA‐Encoded Chemical Libraries on Carbonic Anhydrase IX‐Expressing Tumor Cells Reveal a Dependence on Ligand Valence (Chem. Eur. J. 35/2021) (2021) (0)
P12.08 Immunocytokines are a novel immunotherapeutic approach against glioblastoma (2019) (0)
Use of NMR spectroscopy for the study of small proteins in the native and in the urea-unfolded form (1992) (0)
Abstract 5563: Kinetically-controlled release of blocking molecules for the targeted enhancement of therapeutic activity in antibody-cytokine fusion proteins (2018) (0)
A chemically-defined trifunctional antibody-cytokine-drug conjugate with potent anti- tumor activity Running Title: An antibody-cytokine-drug conjugate with anti-tumor activity (2014) (0)
Immunohistochemical evaluation of the oncofetal isoforms of fibronectin and tenascin-C in fresh frozen lung cancer specimens (2009) (0)
Evaluation of the radiolabeled human recombinant mini-antibody 131I-L19SIP in patients (pts) with cancer: Results of a phase I/II study. (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dario Neri?

Dario Neri is affiliated with the following schools:

University of Hull
ETH Zurich
University of Siena
University of Zurich
University of Bologna

Dario Neri's Academic­Influence.com Rankings

Dario Neri's Degrees

Why Is Dario Neri Influential?

Dario Neri's Published Works

Published Works

What Schools Are Affiliated With Dario Neri?

Dario Neri's AcademicInfluence.com Rankings